Effects of thyrotropin-releasing hormone on human myometrium and umbilical vasculature in vitro

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 1, 2004, Pages 246-251

  Potter, S M ^a   Astbury, K ^a   Morrison, J J ^a,b  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Human myometrium; Thyrotropin releasing hormone; Umbilical artery; Umbilical vein

Indexed keywords

PROTIRELIN;

ARTICLE; CESAREAN SECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTIVE SURGERY; EVALUATION; HUMAN; HUMAN TISSUE; MUSCLE ISOMETRIC CONTRACTION; PRIORITY JOURNAL; THYROTROPIN RELEASE; UMBILICAL ARTERY; UMBILICAL VEIN; UTERUS BIOPSY; UTERUS RELAXATION;

EID: 0742269635     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(03)00853-6     Document Type: Article

References (15)

1. Crowther CA, Alfirevic Z. Prenatal thyrotropin-releasing hormone prior to preterm delivery [review]. Cochrane Database Syst Rev 2000;2:CD000020.
2. ACTOBAT study group. Australian collaborative trial of antenatal thyrotropin-releasing hormone (ACTOBAT) for prevention of neonatal respiratory disease. Lancet 1995;345:877-82.
3. Gross I, Moya FR. Is there a role for antenatal TRH therapy for the prevention of neonatal lung disease? Semin Perinatol 2001;25: 406-16.
4. Rosario DJ, Woo HH, Parkhouse H, Chapple CR. Effects of intravenous thyrotropin-releasing hormone on urethral closure pressure in females with voiding dysfunction. Eur Urol 1995;28: 64-7.
5. Petkova-Kirova PS, Lubomirov LT, Gagov HS, Kolev VB, Duridanova DB. Thyrotropin-releasing hormone activates KCa channels in gastric smooth muscle cells via intracellular Ca2+ release. Gen Physiol Biophys 2001;20:43-60.
6. Oturai PS, Friberg L, Sam I, Perrild H. Effects of thyrotropin-releasing hormone on regional cerebral blood flow in man. Acta Endocrinologica 1992;126:243-6.
7. Rizzo G, Capponi A, Rinaldo D, Arduini D, Romanini C. Effects of thyrotropin-releasing hormone on cardiac and extracardiac flows of appropriately grown and growth-retarded fetuses. Ultrasound Obstet Gynaecol 1995;6:8-14.
8. Fukusumi S, Ogi K, Onda H, Hinuma S. Distribution of thyrotropin- releasing hormone receptor mRNA in rat peripheral tissues. Regul Pept 1995;57:115-21.
9. Bajora R, Stagiannis KD, Fisk NM. Effects of antenatal administration of thyrotropin-releasing hormone on fetal flow velocity waveforms. Arch Dis Child Fetal Neonatal Ed 1997;77: F127-F30.
10. Slattery MM, O'Leary MJ, Morrison JJ. Effect of parathyroid hormone-related peptide (PTHrP) on human and rat myometrial contractility in vitro. Am J Obstet Gynecol 2001;184:625-9.
11. Dennedy MC, Houlihan DD, Morrison JJ. Beta-2 and beta-3 adrenoceptor agonists: Human myometrial selectivity and effects on umbilical artery resistance. Am J Obstet Gynecol 2002;187:641-7.
12. Potter SM, Dennedy MC, Morrison JJ. Corticosteroids and fetal vasculature: effects of hydrocortisone, dexamethasone and betamethasone on human umbilical artery. BJOG 2002;109: 1126-31.
13. Heuer H. Thyrotropin-releasing hormone (TRH), a signal peptide of the central nervous system. Acta Med Austriaca 1999;26:119-22.
14. Nurminen ML, Paakkari I. Role of peripheral and central catecholaminergic and cholinergic mechanisms in the cardiovascular effects of thyrotropin-releasing hormone. Neuropeptides 1991;20:247-53.
15. Ballard PL, Ballard RA, Cressy RK, Padbury J, Polk OH, Bracken M, et al. Plasma thyroid hormones and prolactin in premature infants and their mothers after prenatal treatment with thyrotropin-releasing hormone. Pediatr Res 1992;32:673-8.